Dark horse laquinimod reveals potential as MS pill | Evaluate
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Letter to investigators involved in the Arpeggio study of Laquinimod …
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
laquinimod
Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Laquinimod - Wikipedia
Teva drops development of laquinimod - PharmaTimes
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis | NEJM
Linomide - Wikipedia
Laquinimod | C19H17ClN2O3 - PubChem
With EU knockback laquinimod's irrelevance is all but assured | Evaluate
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
